The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).
Kimmo Porkka
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis
Michael J. Mauro
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Bristol-Myers Squibb
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Francois-Xavier Mahon
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Lewis C. Strauss
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
William J. Geese
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Glenn Scott Kroog
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Satu Mustjoki
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis